Published in PLoS One on February 16, 2012
K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis (2002) 81.62
[''R"--project for statistical computing]. Ugeskr Laeger (2008) 41.69
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 32.41
Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA (2001) 8.80
Dangers of rosuvastatin identified before and after FDA approval. Lancet (2004) 3.62
Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol (2006) 2.84
The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. Nephrol Dial Transplant (2006) 2.50
Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study. The Nord-Trøndelag Health Study (HUNT), Norway. Am J Kidney Dis (2003) 2.44
Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int (2001) 2.35
Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int (2008) 2.34
Meta-analysis: the effect of statins on albuminuria. Ann Intern Med (2006) 2.19
An overview of the objectives of and the approaches to propensity score analyses. Eur Heart J (2011) 1.98
Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. J Am Soc Nephrol (2004) 1.48
Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia (1999) 1.45
Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. J Am Soc Nephrol (2004) 1.41
Applying propensity score methods in medical research: pitfalls and prospects. Med Care Res Rev (2010) 1.27
Proteinuria as complication of simvastatin treatment. Lancet (1990) 1.19
Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens (1998) 1.19
New definition of microalbuminuria in hypertensive subjects: association with incident coronary heart disease and death. Hypertension (2005) 1.17
Albumin transport and processing by the proximal tubule: physiology and pathophysiology. Curr Opin Nephrol Hypertens (2007) 1.03
Simvastatin and tempol protect against endothelial dysfunction and renal injury in a model of obesity and hypertension. Am J Physiol Renal Physiol (2009) 0.95
Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1). Diabet Med (2011) 0.94
Microalbuminuria in diabetic and hypertensive patients and the general population--consequences of various diagnostic criteria--the Nord-Trøndelag Health Study (HUNT). Scand J Urol Nephrol (2003) 0.94
Rosuvastatin protects against angiotensin II-induced renal injury in a dose-dependent fashion. J Hypertens (2009) 0.89
Propensity score methods and their application in nephrology research. J Nephrol (2011) 0.85
Renal tubular toxicity of HMG-CoA reductase inhibitors. Nephrol Dial Transplant (2004) 0.84
Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients. Diabetes Res Clin Pract (2005) 0.81
Dose-dependent effect of rosuvastatin treatment on urinary protein excretion. J Cardiovasc Pharmacol Ther (2007) 0.80
Towards a rational screening strategy for albuminuria: results from the unreferred renal insufficiency trial. PLoS One (2010) 0.78
Effects of rosuvastatin on glomerular capillary size-selectivity function in rats with renal mass ablation. Am J Nephrol (2007) 0.77
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med (2013) 6.01
Acute renal failure. Lancet (2005) 5.60
Mapping of pelvic lymph node metastases in prostate cancer. Eur Urol (2012) 4.26
EBPG on Vascular Access. Nephrol Dial Transplant (2007) 3.26
Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol (2014) 3.06
Hypomagnesemia and the risk of death and GFR decline in chronic kidney disease. Am J Med (2013) 2.96
The burden of kidney disease: improving global outcomes. Kidney Int (2004) 2.94
Management of crush-related injuries after disasters. N Engl J Med (2006) 2.90
Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol (2009) 2.89
Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol (2008) 2.76
EBPG guideline on nutrition. Nephrol Dial Transplant (2007) 2.68
Recurrence of mitral valve regurgitation after mitral valve repair in degenerative valve disease. Circulation (2003) 2.67
Acute kidney injury: an increasing global concern. Lancet (2013) 2.61
Urinary and serum biomarkers for the diagnosis of acute kidney injury: an in-depth review of the literature. Nephrol Dial Transplant (2012) 2.59
Acute kidney injury. Lancet (2008) 2.44
The importance of standardization of creatinine in the implementation of guidelines and recommendations for CKD: implications for CKD management programmes. Nephrol Dial Transplant (2005) 2.38
Recommendation for the management of crush victims in mass disasters. Nephrol Dial Transplant (2012) 2.27
Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant (2008) 2.24
Cardiovascular disease in haemodialysis and peritoneal dialysis: arguments pro peritoneal dialysis. Nephrol Dial Transplant (2006) 2.17
Noninvasive assessment of local pulse pressure: importance of brachial-to-radial pressure amplification. Hypertension (2005) 2.15
Clinical practice guideline on diagnosis and treatment of hyponatraemia. Nephrol Dial Transplant (2014) 2.10
Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant (2009) 2.06
Sense of coherence and perceived physical health explain the better quality of life in adolescents with congenital heart disease. Eur J Cardiovasc Nurs (2013) 2.03
The changing epidemiology of acute renal failure. Nat Clin Pract Nephrol (2006) 2.01
Prosthesis-patient mismatch predicts structural valve degeneration in bioprosthetic heart valves. Circulation (2010) 1.95
A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant (2012) 1.94
Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int (2009) 1.93
Chronic kidney disease in adults--UK guidelines for identification, management and referral. Nephrol Dial Transplant (2006) 1.91
EBPG guideline on dialysis strategies. Nephrol Dial Transplant (2007) 1.90
Association of dialysate bicarbonate concentration with mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis (2013) 1.90
Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol (2012) 1.90
Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics (2010) 1.90
Educating end-stage renal disease patients on dialysis modality selection: clinical advice from the European Renal Best Practice (ERBP) Advisory Board. Nephrol Dial Transplant (2010) 1.90
The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int (2004) 1.83
Complex compartmental behavior of small water-soluble uremic retention solutes: evaluation by direct measurements in plasma and erythrocytes. Am J Kidney Dis (2007) 1.77
Motor and functional recovery after stroke: a comparison of 4 European rehabilitation centers. Stroke (2007) 1.68
Validation of a patient-specific hemodynamic computational model for surgical planning of vascular access in hemodialysis patients. Kidney Int (2013) 1.68
The personal dialysis capacity test is superior to the peritoneal equilibration test to discriminate inflammation as the cause of fast transport status in peritoneal dialysis patients. Clin J Am Soc Nephrol (2005) 1.67
EBPG guideline on haemodynamic instability. Nephrol Dial Transplant (2007) 1.65
Why less success of the peritoneal dialysis programmes in Europe? Nephrol Dial Transplant (2008) 1.65
Clinical findings in the renal victims of a catastrophic disaster: the Marmara earthquake. Nephrol Dial Transplant (2002) 1.60
Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med (2010) 1.59
Clinical characteristics of patients developing ARF due to sepsis/systemic inflammatory response syndrome: results of a prospective study. Am J Kidney Dis (2004) 1.58
CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl (2008) 1.57
P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant (2006) 1.53
Severity of sepsis-induced acute kidney injury in a novel mouse model is age dependent. Crit Care Med (2012) 1.52
Detection of angiotensin II in supernatants of stimulated mononuclear leukocytes by matrix-assisted laser desorption ionization time-of-flight/time-of-flight mass analysis. Hypertension (2005) 1.52
Relationship between fluid status and its management on acute renal failure (ARF) in intensive care unit (ICU) patients with sepsis: a prospective analysis. J Nephrol (2005) 1.51
Catheter-related blood stream infections (CRBSI): a European view. Nephrol Dial Transplant (2010) 1.50
Defining acute renal failure: RIFLE and beyond. Clin J Am Soc Nephrol (2006) 1.49
Acute central hemodynamic effects of a volume exchange in peritoneal dialysis. Perit Dial Int (2008) 1.49
Therapeutic interventions favorably influencing delayed and slow graft function in kidney transplantation: mission impossible? Transplantation (2008) 1.49
The effect of magnesium supplements on early post-transplantation glucose metabolism: a randomized controlled trial. Transpl Int (2014) 1.48
Acute renal failure due to crush syndrome during Marmara earthquake. Am J Kidney Dis (2002) 1.47
Intraluminal thrombus in facilitated versus primary percutaneous coronary intervention: an angiographic substudy of the ASSENT-4 PCI (Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention) trial. J Am Coll Cardiol (2011) 1.45
Initiation of dialysis--is the problem solved by NECOSAD? Nephrol Dial Transplant (2002) 1.42
Prognostic value of aortic stiffness and calcification for cardiovascular events and mortality in dialysis patients: outcome of the calcification outcome in renal disease (CORD) study. Clin J Am Soc Nephrol (2010) 1.40
European Renal Best Practice (ERBP) Guideline development methodology: towards the best possible guidelines. Nephrol Dial Transplant (2013) 1.40
The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. Eur Heart J (2007) 1.38
Length of time on peritoneal dialysis and encapsulating peritoneal sclerosis: position paper for ISPD. Perit Dial Int (2009) 1.34
Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. Nephrol Dial Transplant (2010) 1.34
The gut: the forgotten organ in uremia? Blood Purif (2010) 1.33
When to start dialysis: updated guidance following publication of the Initiating Dialysis Early and Late (IDEAL) study. Nephrol Dial Transplant (2011) 1.30
Epidemiology of peritoneal dialysis: a story of believers and nonbelievers. Nat Rev Nephrol (2009) 1.29
Use of time by stroke patients: a comparison of four European rehabilitation centers. Stroke (2005) 1.28
Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant (2013) 1.28
Protein-bound toxins--update 2009. Semin Dial (2009) 1.28
From curing to caring: one character change makes a world of difference. Issues related to withholding/withdrawing renal replacement therapy (RRT) from patients with important co-morbidities. Nephrol Dial Transplant (2004) 1.26
The rise of prevalence and the fall of mortality of patients with acute renal failure: what the analysis of two databases does and does not tell us. J Am Soc Nephrol (2006) 1.25
Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis. Am J Kidney Dis (2002) 1.24
Effective removal of protein-bound uraemic solutes by different convective strategies: a prospective trial. Nephrol Dial Transplant (2008) 1.23
Role of symmetric dimethylarginine in vascular damage by increasing ROS via store-operated calcium influx in monocytes. Nephrol Dial Transplant (2008) 1.23
What is new in uremic toxicity? Pediatr Nephrol (2008) 1.23
Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease. Clin J Am Soc Nephrol (2011) 1.20
Uridine adenosine tetraphosphate: a novel endothelium- derived vasoconstrictive factor. Nat Med (2005) 1.19
Reimbursement of dialysis: a comparison of seven countries. J Am Soc Nephrol (2012) 1.17
Clinical practice guideline on diagnosis and treatment of hyponatraemia. Intensive Care Med (2014) 1.17
Body composition, hydration, and related parameters in hemodialysis versus peritoneal dialysis patients. Perit Dial Int (2010) 1.16
Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. Kidney Int (2012) 1.16
Aortic stiffness and central wave reflections predict outcome in renal transplant recipients. Hypertension (2011) 1.15